"{\"name\": \"Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer\", \"sent_tag\": {\"11\": [[\"It\", \"O\"], [\"follows\", \"O\"], [\"the\", \"O\"], [\"recent\", \"O\"], [\"exclusive\", \"O\"], [\"licensing\", \"O\"], [\"agreement\", \"O\"], [\"and\", \"O\"], [\"a\", \"O\"], [\"co-development\", \"O\"], [\"partnership\", \"O\"], [\"signed\", \"O\"], [\"with\", \"O\"], [\"the\", \"O\"], [\"Baylor\", \"ORGANIZATION\"], [\"College\", \"ORGANIZATION\"], [\"of\", \"ORGANIZATION\"], [\"Medicine\", \"ORGANIZATION\"], [\"(Baylor)\", \"ORGANIZATION\"], [\"and\", \"O\"], [\"the\", \"O\"], [\"acquisition\", \"O\"], [\"of\", \"O\"], [\"Delenex\", \"O\"], [\"Therapeutics,\", \"O\"], [\"all\", \"O\"], [\"of\", \"O\"], [\"which\", \"O\"], [\"have\", \"O\"], [\"significantly\", \"O\"], [\"added\", \"O\"], [\"to\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medicas\", \"ORGANIZATION\"], [\"armoury\", \"O\"], [\"as\", \"O\"], [\"it\", \"O\"], [\"seeks\", \"O\"], [\"to\", \"O\"], [\"capitalise\", \"O\"], [\"on\", \"O\"], [\"the\", \"O\"], [\"market\", \"O\"], [\"opportunity\", \"O\"], [\"for\", \"O\"], [\"next-generation\", \"O\"], [\"products\", \"O\"], [\"which\", \"O\"], [\"harness\", \"O\"], [\"the\", \"O\"], [\"human\", \"O\"], [\"immune\", \"O\"], [\"response\", \"O\"], [\"to\", \"O\"], [\"fight\", \"O\"], [\"cancer.\", \"O\"]], \"1\": [[\"The\", \"O\"], [\"collaboration\", \"O\"], [\"also\", \"O\"], [\"provides\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"with\", \"O\"], [\"an\", \"O\"], [\"exclusive\", \"O\"], [\"worldwide\", \"O\"], [\"option\", \"O\"], [\"and\", \"O\"], [\"licence\", \"O\"], [\"agreement\", \"O\"], [\"for\", \"O\"], [\"these\", \"O\"], [\"technologies,\", \"O\"], [\"as\", \"O\"], [\"well\", \"O\"], [\"as\", \"O\"], [\"TCR\", \"O\"], [\"gene\", \"O\"], [\"sequences\", \"O\"], [\"for\", \"O\"], [\"the\", \"O\"], [\"development\", \"O\"], [\"and\", \"O\"], [\"commercialisation\", \"O\"], [\"of\", \"O\"], [\"specific\", \"O\"], [\"products.\", \"O\"]], \"3\": [[\"UCL\", \"ORGANIZATION\"], [\"will\", \"O\"], [\"conduct\", \"O\"], [\"the\", \"O\"], [\"preclinical\", \"O\"], [\"and\", \"O\"], [\"early\", \"O\"], [\"clinical\", \"O\"], [\"research\", \"O\"], [\"under\", \"O\"], [\"the\", \"O\"], [\"guidance\", \"O\"], [\"of\", \"O\"], [\"a\", \"O\"], [\"Joint\", \"O\"], [\"Steering\", \"O\"], [\"Committee.\", \"O\"]], \"2\": [[\"The\", \"O\"], [\"collaboration\", \"O\"], [\"builds\", \"O\"], [\"on\", \"O\"], [\"the\", \"O\"], [\"research\", \"O\"], [\"of\", \"O\"], [\"Professor\", \"O\"], [\"Hans\", \"PERSON\"], [\"Stauss\", \"PERSON\"], [\"and\", \"O\"], [\"Professor\", \"O\"], [\"Emma\", \"PERSON\"], [\"Morris\", \"PERSON\"], [\"of\", \"O\"], [\"UCL,\", \"O\"], [\"global\", \"O\"], [\"leaders\", \"O\"], [\"in\", \"O\"], [\"developing\", \"O\"], [\"modified\", \"O\"], [\"TCRs\", \"O\"], [\"for\", \"O\"], [\"cancer\", \"O\"], [\"treatments,\", \"O\"], [\"both\", \"O\"], [\"of\", \"O\"], [\"whom\", \"O\"], [\"are\", \"O\"], [\"based\", \"O\"], [\"at\", \"O\"], [\"the\", \"O\"], [\"Royal\", \"O\"], [\"Free\", \"O\"], [\"Hospital,\", \"O\"], [\"a\", \"O\"], [\"UCL\", \"O\"], [\"Partners\", \"O\"], [\"academic\", \"O\"], [\"health\", \"O\"], [\"science\", \"O\"], [\"centre.\", \"O\"]], \"10\": [[\"Russ\", \"O\"], [\"Cummings,\", \"O\"], [\"CEO\", \"O\"], [\"at\", \"O\"], [\"Imperial\", \"ORGANIZATION\"], [\"Innovations,\", \"O\"], [\"said:\", \"O\"], [\"This\", \"O\"], [\"new\", \"O\"], [\"collaboration\", \"O\"], [\"with\", \"O\"], [\"UCL\", \"ORGANIZATION\"], [\"adds\", \"O\"], [\"the\", \"O\"], [\"modified\", \"O\"], [\"TCR\", \"O\"], [\"technology\", \"O\"], [\"platform\", \"O\"], [\"to\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medicas\", \"ORGANIZATION\"], [\"strategy\", \"O\"], [\"to\", \"O\"], [\"develop\", \"O\"], [\"breakthrough\", \"O\"], [\"treatments\", \"O\"], [\"for\", \"O\"], [\"cancer\", \"O\"], [\"using\", \"O\"], [\"cellular\", \"O\"], [\"immunotherapy\", \"O\"], [\"products.\", \"O\"]], \"12\": [[\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"is\", \"O\"], [\"a\", \"O\"], [\"cellular\", \"O\"], [\"immunotherapy\", \"O\"], [\"company,\", \"O\"], [\"focused\", \"O\"], [\"on\", \"O\"], [\"the\", \"O\"], [\"development,\", \"O\"], [\"manufacture\", \"O\"], [\"and\", \"O\"], [\"marketing\", \"O\"], [\"of\", \"O\"], [\"cell-based\", \"O\"], [\"therapeutics\", \"O\"], [\"for\", \"O\"], [\"the\", \"O\"], [\"treatment\", \"O\"], [\"of\", \"O\"], [\"cancers\", \"O\"], [\"and\", \"O\"], [\"infectious\", \"O\"], [\"disease.\", \"O\"]], \"5\": [[\"Following\", \"O\"], [\"completion\", \"O\"], [\"of\", \"O\"], [\"successful\", \"O\"], [\"first-in-man\", \"O\"], [\"studies,\", \"O\"], [\"the\", \"O\"], [\"products\", \"O\"], [\"will\", \"O\"], [\"transfer\", \"O\"], [\"to\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"for\", \"O\"], [\"later-stage\", \"O\"], [\"clinical\", \"O\"], [\"development\", \"O\"], [\"and\", \"O\"], [\"commercialisation.\", \"O\"]], \"4\": [[\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"will\", \"O\"], [\"support\", \"O\"], [\"the\", \"O\"], [\"product\", \"O\"], [\"development\", \"O\"], [\"work\", \"O\"], [\"with\", \"O\"], [\"its\", \"O\"], [\"substantial\", \"O\"], [\"experience\", \"O\"], [\"in\", \"O\"], [\"manufacturing\", \"O\"], [\"clinical-grade\", \"O\"], [\"cell\", \"O\"], [\"therapies\", \"O\"], [\"and\", \"O\"], [\"establishing\", \"O\"], [\"robust\", \"O\"], [\"production\", \"O\"], [\"processes\", \"O\"], [\"suitable\", \"O\"], [\"for\", \"O\"], [\"industrial\", \"O\"], [\"scale-up.\", \"O\"]], \"6\": [[\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"has\", \"O\"], [\"entered\", \"O\"], [\"into\", \"O\"], [\"an\", \"O\"], [\"exclusive\", \"O\"], [\"licence\", \"O\"], [\"and\", \"O\"], [\"option\", \"O\"], [\"agreement\", \"O\"], [\"with\", \"O\"], [\"UCL\", \"ORGANIZATION\"], [\"Business,\", \"O\"], [\"the\", \"O\"], [\"technology\", \"O\"], [\"commercialisation\", \"O\"], [\"company\", \"O\"], [\"of\", \"O\"], [\"UCL,\", \"O\"], [\"for\", \"O\"], [\"the\", \"O\"], [\"dominant\", \"O\"], [\"TCR\", \"O\"], [\"platform\", \"O\"], [\"patent\", \"O\"], [\"and\", \"O\"], [\"two\", \"O\"], [\"target\", \"O\"], [\"antigens.\", \"O\"]], \"0\": [[\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"and\", \"O\"], [\"UCL\", \"ORGANIZATION\"], [\"collaborate\", \"O\"], [\"to\", \"O\"], [\"develop\", \"O\"], [\"modified\", \"O\"], [\"T\", \"O\"], [\"cell\", \"O\"], [\"receptor\", \"O\"], [\"products\", \"O\"], [\"for\", \"O\"], [\"the\", \"O\"], [\"treatment\", \"O\"], [\"of\", \"O\"], [\"cancer\", \"O\"], [\"Imperial\", \"ORGANIZATION\"], [\"Innovations\", \"ORGANIZATION\"], [\"Group\", \"ORGANIZATION\"], [\"plc\", \"O\"], [\"(AIM:\", \"O\"], [\"IVO\", \"O\"], [\"or\", \"O\"], [\"the\", \"O\"], [\"Group,\", \"O\"], [\"Innovations)\", \"O\"], [\"notes\", \"O\"], [\"todays\", \"O\"], [\"announcement\", \"O\"], [\"by\", \"O\"], [\"portfolio\", \"O\"], [\"company\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"(the\", \"O\"], [\"Company)\", \"O\"], [\"of\", \"O\"], [\"a\", \"O\"], [\"new\", \"O\"], [\"research\", \"O\"], [\"collaboration\", \"O\"], [\"with\", \"O\"], [\"UCL\", \"ORGANIZATION\"], [\"(University\", \"ORGANIZATION\"], [\"College\", \"ORGANIZATION\"], [\"London)\", \"O\"], [\"which\", \"O\"], [\"will\", \"O\"], [\"see\", \"O\"], [\"the\", \"O\"], [\"Company\", \"O\"], [\"utilise\", \"O\"], [\"UCLs\", \"O\"], [\"novel\", \"O\"], [\"T\", \"O\"], [\"cell\", \"O\"], [\"receptor\", \"O\"], [\"(TCR)\", \"O\"], [\"technology\", \"O\"], [\"to\", \"O\"], [\"generate\", \"O\"], [\"leading-edge\", \"O\"], [\"modified\", \"O\"], [\"TCR\", \"O\"], [\"products\", \"O\"], [\"for\", \"O\"], [\"the\", \"O\"], [\"treatment\", \"O\"], [\"of\", \"O\"], [\"cancer.\", \"O\"]], \"9\": [[\"The\", \"O\"], [\"financial\", \"O\"], [\"terms\", \"O\"], [\"of\", \"O\"], [\"this\", \"O\"], [\"transaction\", \"O\"], [\"have\", \"O\"], [\"not\", \"O\"], [\"been\", \"O\"], [\"disclosed.\", \"O\"]], \"8\": [[\"In\", \"O\"], [\"addition,\", \"O\"], [\"UCL\", \"O\"], [\"and\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"have\", \"O\"], [\"signed\", \"O\"], [\"a\", \"O\"], [\"Sponsored\", \"ORGANIZATION\"], [\"Research\", \"ORGANIZATION\"], [\"Agreement\", \"ORGANIZATION\"], [\"under\", \"O\"], [\"which\", \"O\"], [\"Cell\", \"ORGANIZATION\"], [\"Medica\", \"ORGANIZATION\"], [\"will\", \"O\"], [\"fund\", \"O\"], [\"all\", \"O\"], [\"research\", \"O\"], [\"and\", \"O\"], [\"development\", \"O\"], [\"with\", \"O\"], [\"an\", \"O\"], [\"exclusive\", \"O\"], [\"option\", \"O\"], [\"to\", \"O\"], [\"licence\", \"O\"], [\"all\", \"O\"], [\"products\", \"O\"], [\"developed\", \"O\"], [\"within\", \"O\"], [\"the\", \"O\"], [\"collaboration.\", \"O\"]], \"7\": [[\"As\", \"O\"], [\"part\", \"O\"], [\"of\", \"O\"], [\"this\", \"O\"], [\"agreement,\", \"O\"], [\"both\", \"O\"], [\"parties\", \"O\"], [\"can\", \"O\"], [\"bring\", \"O\"], [\"targets\", \"O\"], [\"or\", \"O\"], [\"platform\", \"O\"], [\"technologies\", \"O\"], [\"to\", \"O\"], [\"the\", \"O\"], [\"collaboration,\", \"O\"], [\"aiming\", \"O\"], [\"to\", \"O\"], [\"generate\", \"O\"], [\"leading-edge\", \"O\"], [\"modified\", \"O\"], [\"TCR\", \"O\"], [\"products.\", \"O\"]], \"13\": [[\"As\", \"O\"], [\"at\", \"O\"], [\"31\", \"O\"], [\"January\", \"O\"], [\"2016,\", \"O\"], [\"the\", \"O\"], [\"Group\", \"ORGANIZATION\"], [\"had\", \"O\"], [\"a\", \"O\"], [\"27.0%\", \"O\"], [\"interest\", \"O\"], [\"in\", \"O\"], [\"the\", \"O\"], [\"issued\", \"O\"], [\"share\", \"O\"], [\"capital\", \"O\"], [\"of\", \"O\"], [\"the\", \"O\"], [\"Company\", \"ORGANIZATION\"], [\"with\", \"O\"], [\"such\", \"O\"], [\"interest\", \"O\"], [\"having\", \"O\"], [\"a\", \"O\"], [\"net\", \"O\"], [\"fair\", \"O\"], [\"value\", \"O\"], [\"of\", \"O\"], [\"21.0\", \"O\"], [\"million.\", \"O\"]]}}"